Alloy Therapeutics is a biotech company dedicated to empowering scientists in the relentless pursuit to make better medicine for all.
Lexington, Massachusetts
Joined October 2020
- Tweets36
- Following23
- Followers229
- Likes11
Alloy has been named a winner on @FastCompany's 2026 Best Workplaces for Innovators list in the Biotech, Healthcare, and Life Sciences category. We’re proud of the team, culture, and collaboration behind this recognition. alloytx.com/alloy-therapeuti…
Complex biologics don’t come from a standard playbook.
See how Alloy brings together platform, process, and deep experience across molecular formats to move complex biologics forward with speed and intent.
Watch the final video in our series: youtube.com/watch?v=yTcWcBeO…
Good affinity alone doesn’t make an antibody a strong multispecific building block.
Join Alloy’s Dalton Markrush on Oct. 28 to explore multi-parameter optimization using integrated in vitro + in silico workflows.
11 a.m. ET | Register: alloytx.com/beyond-affinity-…
Alloy Therapeutics, Inc. retweeted
𝗣𝗿𝗶𝘅 𝗚𝗮𝗹𝗶𝗲𝗻 𝟮𝟬𝟮𝟲 𝗻𝗼𝗺𝗶𝗻𝗲𝗲𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱!
#PrixGalien USA nominees for Best Digital Health Solution, Best MedTech, Best Incubators, Accelerators and Equity, & Best Startup have been announced: prn.to/4ci9pOk
From @NYSEWired, Alloy Founder & CEO @errikanderson joined @theCUBE to discuss how AI, proprietary data and new models of collaboration can accelerate drug development—and Alloy’s vision for integrated biotech infrastructure without a competing pipeline.
youtube.com/watch?v=Y1Uvfr0h…
Alloy Therapeutics, Inc. retweeted
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @AlloyTx which has a service provider model of helping other companies develop therapies, recently crossed the $1B valuation mark on their series E and is now fully integrated.
Full video: biotechtv.com/post/alloy-the…
Build in-house or outsource piece by piece. For decades, those were biotech’s options. We believe there’s a third: the PDO — integrated infrastructure designed to help innovators develop better medicines, without competing with them
Read more: linkedin.com/feed/update/urn…
🧬 Explore Alloy’s expanded Genetic Medicines website.
Discover our AntiClastic™ cyclic RNA platform and integrated capabilities for advancing oligonucleotide medicines from concept toward the clinic.
Learn more: alloytx.com/genetic-medicine…
"Alloy's entire business model is to collaborate with others to make medicine." — @errikanderson Anderson
@BosBizJournal on how we got here → bizjournals.com/boston/news/…
Great science alone doesn't build a winning program. The right operating model does. Cantai, Agent Capital, 82VS, and Alloy on what it took to move a bispecific program from company creation to lead candidate.
Watch → youtube.com/watch?v=-Af6Mnb4…
Alloy Therapeutics, Inc. retweeted
Alloy Therapeutics secures $1B valuation, plus Biogen, AbbVie deals in big 2026 - Boston Business Journal bizjournals.com/boston/news/… via @BosBizJournal
Multispecific antibodies aren't harder monoclonals.
They're a different class of molecule. What we've learned building across formats, targets, and indications → alloytx.com/multispecific-an…
Better models start with better data.
Every campaign surfaces patterns you didn't design the experiment to find. The compounding happens when those findings close the loop back into the next design cycle. How we're applying it to antibody discovery → alloytx.com/high-velocity-th…
AI in antibody discovery has shifted failure - from late and expensive to earlier and more manageable.
Durable advantage depends as much on data infrastructure as on model choice. Where AI/ML is delivering, where it's brittle, and what's next: alloytx.com/ai-ml-in-antibod…
The value of AI in drug discovery isn't speed.
It's closing the loop between data generation and decision-making at every stage, from early risk assessment to deep sequencing analysis that surfaces rare, high-value clones.
Part 3 of our AI/ML series → catch the full clip on YT
Format decisions in multispecific development compound. Get them right early and the whole program accelerates. June 23: three vignettes on what integrated discovery infrastructure actually enables.
Register → alloytx.com/webinar-antibody…
Most bispecific programs treat target biology, molecular design, and developability as sequential problems.
Cantai designed against all three from day one.
What that enabled — and what it looked like in practice →alloytx.com/advancing-differ…
Alloy Therapeutics, Inc. retweeted
@errikanderson has founded four unicorns.
And few know his name.
That’s by design.
Because he’s playing a different game.
Most founders ask:
👉 “What company should I build?”
Errik asks:
👉 “What problem space do I want to spend my life in?”
His principle:
Build the business you want to work in for the rest of your career.
That leads to very different outcomes:
• Longer time horizons
• Deeper conviction
• Less interest in exits
Instead of chasing wins, he’s building a compounding machine in biotech.
Not for attention.
For impact.
Errik’s ambition is simple (and insane): help solve cancer.
Backed by people like @peterthiel and @JTLonsdale, he’s quietly helped develop more cancer therapeutics than ANY human in history.
When I asked why he named his family office Ulysses, he said:
“I wanted the most generic name possible—so my kids can build their own legacy.”
That tells you everything you need to know about him.
This episode builds on 16 years of philosophical conversations I’ve been lucky to have with Errik as a friend.
Special shoutout to @ChristopherZook, @atlasventure, @benchmark and @BillAckman mentioned in the episode!
We’d like to thank @AlphaSenseInc for sponsoring this episode!
#Biotech #VentureCapital #PrivateMarkets #DrugDiscovery #Innovation #CapitalAllocation
Full episode👇
youtube.com/watch?v=CPNSTMA8…
Developability risk is a leading cause of biologics failure—often discovered too late.
Our Developability Tech Note outlines how to identify that risk earlier.